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Objectives: Hospital readmission has been an important issue in patients with 
chronic obstructive pulmonary disease (COPD), as it reflects exacerbation of the 
disease and quality of medical care, and incurs high medical expenditures. This 
study aimed to examine pattern and economic burden of readmission, and iden-
tify factors associated with risk of readmission in patients hospitalized for COPD 
in Taiwan. MethOds: The National Health Insurance claims database of a rep-
resentative sample (two million subjects) of Taiwanese population in 2005 was 
adopted for this study. Adult individuals who were discharged from acute hospitals 
for COPD in 2005 were selected and their readmission pattern one-year after dis-
charge were examined. Cox proportional hazards regression models were adopted 
to identify factors associated with risk of readmission. Results: The majority of 
the subjects was male and aged older than 65 years old. The 30-day, 3-month and 
one-year all-cause readmission rates were 28%, 46%, and 69%, respectively. The 
30-day, 3-month and one-year COPD-specific readmission rates were 10%, 17%, 
and 31%, respectively. Approximately one-fourth of the subjects were readmitted 
more than twice during the follow-up. COPD, pneumonia, and respiratory fail-
ure/insufficiency/arrest were the top three most frequent causes for readmission 
during 30 days, 3 months, or one year after discharge. In the one-yar follow-up, 
hospital readmission accounted for 73% of total healthcare expenditures. Gender, 
previous hospitalization history, comorbidities, and length of stay and hospital 
accreditation level of the index hospitalization were associated with risk of all-
cause readmission. Gender, previous hospitalization history, and length of stay and 
hospital accreditation level of the index hospitalization were associated with risk 
of COPD-specific readmission. cOnclusiOns: This study identified patterns and 
causes of short-term and long-term readmission, and factors associated with risk 
of readmission in patients hospitalized for COPD. The information is of importance 
for planning interventions to reduce hospital readmission rate.
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Objectives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting 
beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was 
developed to assess the budget impact of switching adult patients with persistent 
asthma and chronic obstructive pulmonary disease (COPD) from market-leading 
DPIs in the Italy – budesonide/formoterol Turbohaler® and fluticasone/salmeterol 
Diskus® – to DuoResp® Spiromax®. The potential cost benefit of improved inhala-
tion technique due to the innovative characteristics of the Spiromax® inhaler was 
also investigated. MethOds: The eligible adult patient population was based on 
current confirmed Italian asthma and COPD diagnosis rates, with the proportion 
of patients receiving FDCs based on market research data. Costs of FDCs were 
taken from ”Farmadati Italia” database and costs of scheduled and unscheduled 
healthcare events were based on “Tariffario Regione Lombardia”, with the number 
of events estimated based on publically available UK sources. Frequency of poor 
inhalation technique, and the associated increased risk of unscheduled healthcare 
events, were taken from a large (n= 1,664) cross-sectional, Italian observational 
study. Reduction in the proportion of patients with poor inhalation technique with 
DuoResp® Spiromax® was based on assumption. Results: An estimated 196,419 
adult patients used budesonide/formoterol Turbohaler® and 505,564 fluticasone/
salmeterol Diskus® annually in Italy with 85,442 and 174,451 of these estimated 
to exhibit poor inhalation technique, respectively. Assuming a hypothetical uptake 
of DuoResp® Spiromax®reaching 10.1% in year 5 and assumed Italian prices, the 
model predicted drug cost savings totalling € 53.66 million. Furthermore, 33,948 
unscheduled healthcare events could be avoided due to the predicted improve-
ment in inhalation technique with DuoResp® Spiromax® compared with these 
DPIs, resulting in further savings of € 4.12 million. cOnclusiOns: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent dis-
ease with a significant economic burden to the UK National Health Service (NHS). 
NICE recommends maintenance treatment including inhaled bronchodilator 
medications, such as long-acting muscarinic antagonists (LAMAs) and long-acting 
beta-2-agonists (LABAs). The objective of this model was to quantify the budget 
impact to the NHS of switching patients with moderate to very severe COPD from 
tiotropium to tiotropium + olodaterol Respimat®, compared with remaining on 
tiotropium monotherapy. MethOds: The model used a deterministic individual-
level Markov approach to compare scenarios with and without the introduction of 
tiotropium + olodaterol Respimat®into the health economy. Patients progressed 
through the model based on their individual FEV1 values at baseline and their 
post-treatment FEV1 value over 5 years. Relative treatment effects (estimated from a 
adequate response. The aim of this study was to compare use of xanthines in the 
treatment of chronic respiratory diseases between Serbia and the Scandinavian 
countries in the period from 2004 to 2013. MethOds: The data on utilization of 
drugs for obstructive airway diseases (ATC group R03) during the ten-year period 
(2004-2013) were retrieved by a retrospective, observational, population-based study, 
from the Medicines and Medical Devices Agency of Serbia, Finnish Medicines Agency 
Fimea, Danish Statens Serum Institut and Norwegian Institute of Public Health. 
ATC/DDD methodology was applied and the results were expressed in defined 
daily doses per 1000 inhabitants per day (DID). Results: While the utilization of 
xanthines (R03DA) showed a significant tendency to decrease in all Scandinavian 
countries during the whole observed period of time (4.4-fold in Denmark, 3.46-fold 
in Norway and 2.38-fold in Finland), in Serbia on the other hand, xanthines rep-
resented the most used drugs in the R03 group, with no clear decrease tendency. 
In 2013, xanthines accounted for less than 2% of total use of drugs in R03 group 
in Finland, Norway and Denmark (1.25 DID, 0.61 DID and 0.50 DID, respectively), 
versus 26% (7.11 DID) in Serbia. cOnclusiOns: The large differences in utiliza-
tion of xanthines between Serbia and other observed countries may suggest con-
siderable lower number of exacerbations of COPD in the Scandinavian countries 
due to better control of chronic respiratory diseases. Acknowledgement: This 
work was supported by the Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina, project No. 114-451-2458/2011 
and by the Ministry of Education, Science and Technological Development, Republic 
of Serbia, project No. 41012.
PRS13
mAnAgEmEnT Of SORE ThROAT In COmmunITY PhARmACY In fRAnCE: A 
nATIOnAL OBSERvATIOnAL STuDY
Berthélemy O1, Berdeaux G2, Auges M2, Bruel P2
1Pa-Pri-Ka, Paris, France, 2Pierre Fabre, boulogne billancourt, France
Objectives: A previous study was conducted in France, in 2013, to evaluate the 
physicians’ prescribing practices related to sore throat. Special attention was paid 
to the use of rapid diagnostic test (TROD). The present study aims at describing how 
sore throat is managed at the community pharmacy-level and at identifying the 
patients’ expectations concerning this condition. MethOds: This was a national 
observational study conducted in community pharmacies distributed around 
France. It included two components: a questionnaire for pharmacists, administered 
by phone, and a self-administered survey submitted to adult patients spontaneously 
consulting pharmacists for sore throat. For the patient population, the data collected 
consisted in demographics, severity of sore throat and expectations. The pharma-
cists were interviewed on the type of products and advice delivered. Results: A 
total of 167 pharmacies were included in the study and 1663 patient questionnaires 
were analyzed. Data collected revealed that most patients (72%) seek pharmacists’ 
advice for sore throat in the first 48 hours after onset and expect in priority a relief of 
difficulty swallowing and/or pain. Most patients suffered from at least one asso-
ciated symptom such as running nose or headache. About 40% of patients were 
advised to consult a physician especially when sore throat lasted longer or was 
associated to a higher number of concomitant symptoms. Combinations of anti-
septic and local anesthetic represent the most frequently advised product for sore 
throat in pharmacies. TROD were not currently offered in most pharmacies (86%) but 
2 pharmacists out of 3 consider delivering it in the future depending on adequate 
training and economic return. cOnclusiOns: The management of sore throat in 
pharmacies largely relies on over-the-counter medications. A wider availability of 
TROD could enable a better disease management and relevant referral to physicians 
in the case of bacterial involvement.
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Objectives: Tobacco consumption is a major public health concern. Every six 
seconds someone dies due to smoking and every second smoker will die from 
smoking-related disease. Smoking double the risk of cardiovascular morbidity and 
all-cause mortality, but smoking cessation significantly reduces this risk. In order to 
best target resources for intervention, this study identified subgroups in a generaliz-
able population who have the lowest smoking cessation rates. MethOds: This is a 
population-based retrospective observational study that assessed cessation rates 
among members of Clalit Health Services (Clalit), the largest health maintenance 
organization in Israel, who were aged 18 and older and reported that they were 
current smokers between 2010 and 2014. Results: There are about 642,000 Clalit 
members who reported that they were current smokers during the past between 
2010 and 2014 (consistent with the national rate of 21.1% in 2014). Of those 14.1% 
reported in 2014 that they quit smoking, versus 11.0% of the smokers reported that 
they had quit smoking in 2011. Cessation rates were lowest among women of certain 
age groups: 7.2% for those aged 18-21 and 13.8% for those aged 45-54 versus 19.9% 
for those aged 25-34, and 22.5% for those aged 65-74. Smokers from lower socioeco-
nomic status had lower smoking cessation rates compared to higher socioeconomic 
status (11.0% vs. 19.0%, respectively). cOnclusiOns: As of 2014, only one in seven 
currents smokers reports quitting and members from low socioeconomic status and 
young and midlife-age females have the lowest smoking cessation rates. Therefore, 
healthcare providers and smoking cessation interventions should consider focus 
on those populations.
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